Identification and evaluation of novel protective antigens for the development of a candidate tuberculosis subunit vaccine

Elena Stylianou, Rachel Harrington-Kandt, Julia Beglov, Naomi Bull, Nawamin Pinpathomrat, Gwendolyn M. Swarbrick, Deborah Lewinsohn, David Lewinsohn, Helen McShane

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The development of a vaccine against tuberculosis (TB), a disease caused by Mycobacterium tuberculosis, is urgently needed. The only currently available vaccine, M. bovis BCG, has variable efficacy. One approach in the global vaccine development effort is focused on boosting BCG using subunit vaccines. The identification of novel antigens for inclusion in subunit vaccines is a critical step in the TB vaccine development pathway. We selected four novel mycobacterial antigens recognized during the course of human infection. A replication-deficient chimpanzee adenovirus (ChAdOx1) was constructed to express each antigen individually, and these vectors were evaluated for protective efficacy in murine M. tuberculosis challenge experiments. One antigen, PPE15 (Rv1039c), conferred significant and reproducible protection when administered alone and as a boost to BCG vaccination. We identified immunodominant epitopes to define the protective immune responses using tetramers and intravascular staining. Lung parenchymal CD4+ and CD8+ CXCR3+ KLRG1- T cells, previously associated with protection against M. tuberculosis, were enriched in the vaccinated groups compared to the control groups. Further work to evaluate the protective efficacy of PPE15 in more stringent preclinical animal models, together with the identification of further novel protective antigens using this selection strategy, is now merited.

Original languageEnglish (US)
Article numbere00014-18
JournalInfection and Immunity
Volume86
Issue number7
DOIs
StatePublished - Jul 1 2018

Fingerprint

Tuberculosis Vaccines
Subunit Vaccines
Antigens
Mycobacterium bovis
Mycobacterium tuberculosis
Vaccines
Immunodominant Epitopes
Pan troglodytes
Adenoviridae
Vaccination
Animal Models
Staining and Labeling
T-Lymphocytes
Lung
Control Groups
Infection

Keywords

  • Mycobacterium tuberculosis
  • Tuberculosis
  • Vaccines
  • Viral vectors

ASJC Scopus subject areas

  • Parasitology
  • Microbiology
  • Immunology
  • Infectious Diseases

Cite this

Stylianou, E., Harrington-Kandt, R., Beglov, J., Bull, N., Pinpathomrat, N., Swarbrick, G. M., ... McShane, H. (2018). Identification and evaluation of novel protective antigens for the development of a candidate tuberculosis subunit vaccine. Infection and Immunity, 86(7), [e00014-18]. https://doi.org/10.1128/IAI.00014-18

Identification and evaluation of novel protective antigens for the development of a candidate tuberculosis subunit vaccine. / Stylianou, Elena; Harrington-Kandt, Rachel; Beglov, Julia; Bull, Naomi; Pinpathomrat, Nawamin; Swarbrick, Gwendolyn M.; Lewinsohn, Deborah; Lewinsohn, David; McShane, Helen.

In: Infection and Immunity, Vol. 86, No. 7, e00014-18, 01.07.2018.

Research output: Contribution to journalArticle

Stylianou E, Harrington-Kandt R, Beglov J, Bull N, Pinpathomrat N, Swarbrick GM et al. Identification and evaluation of novel protective antigens for the development of a candidate tuberculosis subunit vaccine. Infection and Immunity. 2018 Jul 1;86(7). e00014-18. https://doi.org/10.1128/IAI.00014-18
Stylianou, Elena ; Harrington-Kandt, Rachel ; Beglov, Julia ; Bull, Naomi ; Pinpathomrat, Nawamin ; Swarbrick, Gwendolyn M. ; Lewinsohn, Deborah ; Lewinsohn, David ; McShane, Helen. / Identification and evaluation of novel protective antigens for the development of a candidate tuberculosis subunit vaccine. In: Infection and Immunity. 2018 ; Vol. 86, No. 7.
@article{aff3e1e5732f4ee6a4f569b15d54aacf,
title = "Identification and evaluation of novel protective antigens for the development of a candidate tuberculosis subunit vaccine",
abstract = "The development of a vaccine against tuberculosis (TB), a disease caused by Mycobacterium tuberculosis, is urgently needed. The only currently available vaccine, M. bovis BCG, has variable efficacy. One approach in the global vaccine development effort is focused on boosting BCG using subunit vaccines. The identification of novel antigens for inclusion in subunit vaccines is a critical step in the TB vaccine development pathway. We selected four novel mycobacterial antigens recognized during the course of human infection. A replication-deficient chimpanzee adenovirus (ChAdOx1) was constructed to express each antigen individually, and these vectors were evaluated for protective efficacy in murine M. tuberculosis challenge experiments. One antigen, PPE15 (Rv1039c), conferred significant and reproducible protection when administered alone and as a boost to BCG vaccination. We identified immunodominant epitopes to define the protective immune responses using tetramers and intravascular staining. Lung parenchymal CD4+ and CD8+ CXCR3+ KLRG1- T cells, previously associated with protection against M. tuberculosis, were enriched in the vaccinated groups compared to the control groups. Further work to evaluate the protective efficacy of PPE15 in more stringent preclinical animal models, together with the identification of further novel protective antigens using this selection strategy, is now merited.",
keywords = "Mycobacterium tuberculosis, Tuberculosis, Vaccines, Viral vectors",
author = "Elena Stylianou and Rachel Harrington-Kandt and Julia Beglov and Naomi Bull and Nawamin Pinpathomrat and Swarbrick, {Gwendolyn M.} and Deborah Lewinsohn and David Lewinsohn and Helen McShane",
year = "2018",
month = "7",
day = "1",
doi = "10.1128/IAI.00014-18",
language = "English (US)",
volume = "86",
journal = "Infection and Immunity",
issn = "0019-9567",
publisher = "American Society for Microbiology",
number = "7",

}

TY - JOUR

T1 - Identification and evaluation of novel protective antigens for the development of a candidate tuberculosis subunit vaccine

AU - Stylianou, Elena

AU - Harrington-Kandt, Rachel

AU - Beglov, Julia

AU - Bull, Naomi

AU - Pinpathomrat, Nawamin

AU - Swarbrick, Gwendolyn M.

AU - Lewinsohn, Deborah

AU - Lewinsohn, David

AU - McShane, Helen

PY - 2018/7/1

Y1 - 2018/7/1

N2 - The development of a vaccine against tuberculosis (TB), a disease caused by Mycobacterium tuberculosis, is urgently needed. The only currently available vaccine, M. bovis BCG, has variable efficacy. One approach in the global vaccine development effort is focused on boosting BCG using subunit vaccines. The identification of novel antigens for inclusion in subunit vaccines is a critical step in the TB vaccine development pathway. We selected four novel mycobacterial antigens recognized during the course of human infection. A replication-deficient chimpanzee adenovirus (ChAdOx1) was constructed to express each antigen individually, and these vectors were evaluated for protective efficacy in murine M. tuberculosis challenge experiments. One antigen, PPE15 (Rv1039c), conferred significant and reproducible protection when administered alone and as a boost to BCG vaccination. We identified immunodominant epitopes to define the protective immune responses using tetramers and intravascular staining. Lung parenchymal CD4+ and CD8+ CXCR3+ KLRG1- T cells, previously associated with protection against M. tuberculosis, were enriched in the vaccinated groups compared to the control groups. Further work to evaluate the protective efficacy of PPE15 in more stringent preclinical animal models, together with the identification of further novel protective antigens using this selection strategy, is now merited.

AB - The development of a vaccine against tuberculosis (TB), a disease caused by Mycobacterium tuberculosis, is urgently needed. The only currently available vaccine, M. bovis BCG, has variable efficacy. One approach in the global vaccine development effort is focused on boosting BCG using subunit vaccines. The identification of novel antigens for inclusion in subunit vaccines is a critical step in the TB vaccine development pathway. We selected four novel mycobacterial antigens recognized during the course of human infection. A replication-deficient chimpanzee adenovirus (ChAdOx1) was constructed to express each antigen individually, and these vectors were evaluated for protective efficacy in murine M. tuberculosis challenge experiments. One antigen, PPE15 (Rv1039c), conferred significant and reproducible protection when administered alone and as a boost to BCG vaccination. We identified immunodominant epitopes to define the protective immune responses using tetramers and intravascular staining. Lung parenchymal CD4+ and CD8+ CXCR3+ KLRG1- T cells, previously associated with protection against M. tuberculosis, were enriched in the vaccinated groups compared to the control groups. Further work to evaluate the protective efficacy of PPE15 in more stringent preclinical animal models, together with the identification of further novel protective antigens using this selection strategy, is now merited.

KW - Mycobacterium tuberculosis

KW - Tuberculosis

KW - Vaccines

KW - Viral vectors

UR - http://www.scopus.com/inward/record.url?scp=85050107942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050107942&partnerID=8YFLogxK

U2 - 10.1128/IAI.00014-18

DO - 10.1128/IAI.00014-18

M3 - Article

C2 - 29661928

AN - SCOPUS:85050107942

VL - 86

JO - Infection and Immunity

JF - Infection and Immunity

SN - 0019-9567

IS - 7

M1 - e00014-18

ER -